Table 1. Characteristics of patients and... | American Society of Hematology

Table 1.

Characteristics of patients and grafts (grouped by diagnoses)

UPN	Age (y)/sex	Disease + status	Therapy before HCT	Contraindications to conventional HCT	Mos. from Dx to HCT	Source of HSC	CD34⁺ cells × 10⁶/kg	CD3⁺ cells × 10⁸/kg	HLA mismatch
UPN	Age (y)/sex	Disease + status	Therapy before HCT	Contraindications to conventional HCT	Mos. from Dx to HCT	Source of HSC	CD34⁺ cells × 10⁶/kg	CD3⁺ cells × 10⁸/kg	Rejection vector	GVHD vector
SPN2292	21/M	ALL/CR2	3x Dnr/Vcr/Asp/Pred, MTX, Flu/Ara-C/Ida	Hepatic dysfunction, aspergillosis sinuses	64	Blood	7.1	1.2	^1-153	^1-153
UL755	27/M	ALL/CR2	1x Cy/Dnr/Asp/Vcr, 2x HAM, purinetol/MTX	S.p. ventilation for int. pneumonia + septicemia	59	Blood	6.1	5.3	C^†	C^†
SPN2252	57/F	AML/CR1	2x Ida/Ara-C	Age	5	Marrow	3.5	0.4	^1-153	^1-153
UL676	45/M	AML/CR2	1x Ida/Ara-C, 1x Mito-FLAG	Autologous HCT	15	Blood	5.8	3.1	DQBI^†	DQBI^†
UL652	59/M	AML/CR3	4x Ida/Ara-C, 2x Mito-FLAG, 1x TBI/Ara-C, VP16	Age + autologous HCT	27	Blood	9.6	2.1	A^*	A^*
FH15303	59/F	AML/CR3	3x Ida/Ara-C, 2x Mito/VP16, Topo/Ara-C, i.t. MTX, craniospinal RT	Age	21	Blood	2.6	3.8	^1-153	^1-153
UL637	53/M	AML/CR3	3x Ida/Ara-C, Ara-C/Mito/Ida/VP16, 1x Mito/FLAG	Age + aspergillosis + liver cirrhosis	36	Blood	4.7	5.2	C^*	^‡
FH16411	40/F	AML/CR4	4x Ida/Ara-C, 2x Ara-C, HD-Cy, i.t. MTX, craniospinal RT	Suspected aspergillosis + hepatic dysfunction	21	Blood	16.8	5.5	^1-153	^1-153
UL665	51/F	AML/PR2	3x Ida/Ara-C, 2x Mito-FLAG	Age + s.p. ventilation for int. pneumonia + septicemia	35	Blood	5.00	3.7	^1-153	^1-153
UL668	61/M	AML/progression	4x Ida/Ara-C, 2x Mito/VP16, 3x Mito/FLAG, HD-BuCy/VP16, CHOP, vindesine	Age + autologous HCT	82	Blood	2.87	2.09	^1-153	^1-153
UL680	60/F	AML/progression	1x ICE, 1x HAM, 1x Mito-FLAG, 1x HAM	Age	21	Blood	3.3	1.39	A^B^†C^	A^B^†C^
UL692	48/F	AML/rel1	1x Ida/Ara-C, 3x Mito/Ara-C	Age + Karnofsky 60	12	Blood	14.3	3.7	B^†	B^†
UL656	47/M	CLL/PR	HD-chlorambucil, 6x Flu/Cy	Age + patient decision	9	Blood	21.6	4.5	^1-153	^1-153
UL698	50/M	CLL/PR	6x CHOP, 2x Flu/Cy, 1x Dexa-BEAM	Age + s.p. recurrent septicemias	77	Blood	5.5	3.4	^1-153	^1-153
FH16078	59/M	CLL/rel	Chlorambucil, 14x Flu, 6x Flu/Cy	Age	78	Blood	12.80	2.27	^1-153	^1-153
UL597	48/M	CML/AP	Hu/IFN, 1x Ida/Ara-C, HD-Bu, Hu/IFN	Autologous HCT	41	Blood	10.3	4.6	C^*	C^*
UL641	45/F	CML/AP	1x Ida/Ara-C, IFN/Hu, IFN/Ara-C	Adipositas, hypertension	30	Blood	3.2	2.6	^‡	^‡
UL670	47/M	CML/AP	Hu, Ida/Ara-C, Hu/IFN, HD-Bu, Hu/IFN	Autologous HCT	42	Marrow	1.7	0.22	C	C
UL672	50/F	CML/CP	1x Ida/Ara-C, IFN/Hu	Age	32	Blood	6	3.9	^1-153	^1-153
UL695	46/M	CML/AP	Hu, IFN, Ida/Ara-C, HD-Bu	Autologous HCT	63	Blood	14.2	3.8	A^†	A^†
UL709	62/M	CML/CP	Hu/IFN, Ara-C	Age	24	Blood	5.3	6.2	^1-153	^1-153
UL725	57/M	CML/CP	Hu, IFN, Hu	Age	80	Blood	4.5	1	^1-153	^1-153
UL730	57/M	CML/CP	Hu/IFN	Age	75	Blood	5.8	3.3	C^*	A^† C^*
									DQB1^*	DQB1^*
UL735	57/F	CML/CP	Hu, Ida/Ara-C, IFN/Hu, HD-Bu, Ara-C/IFN, Hu, Tg	Age + autologous HCT	26	Blood	5.5	10	^1-153	^1-153
UL754	54/M	CML/CP2	Hu, IFN, Ida/Ara-C, HD-Bu, IFN, Hu, Vcr/Pred, ST1571, Ida/Ara-C	Age + autologous HCT	74	Blood	6.1	3.4	C^* DRB1^† DQB1^*	C^* DRB1^†
UC001	36/F	CML/AP	Hu/IFN, BU/mel, Ida/Ara-C/DLI, Flu/ATG/TLI, FLAG	Previous HLA-id sibling HCT	24	Marrow	2.76	0.45	^‡	^‡
UC002	33/M	CML/BC	IFN/Hu, Cy/TBI, Mito/Flu/Ara-C, Mylotarg	Previous HLA-matched unrelated HCT	52	Marrow	1.88	0.29	^‡	^‡
FH15764	43/M	Hodgkin disease/rel	3x ABVD, 3x Chl-VPP, Dnr, Vbl, 6x VP16, RT pelvic nodes, L hemipelvis/groin, BEAC	Autologous HCT	32	Blood	5.65	1.54	^1-153	^1-153
UL701	40/M	NHL/refr B-cell	8x CHOP, Vbl/Dexa, Dexa-BEAM, HD-MTX, HD-BEAM, Bu/Thiotepa	2x Autologous HCT	21	Blood	6.2	4.9	A^*	A^*
SPN1463	45/M	NHL/rel diff. large cell	MOPP/ABV, radiotherapy, 2x DHAP, HD-Cy, Vcr, VP16, Mito/Mel, Rituxan, Cy/Flu, Taxol	Autologous HCT	41	Blood	3.60	1.7	C^*	^1-153
FH13715	42/M	NHL/rel MCL	6x CHOP, Cy/VP16, 2x Gemcitabine, 2x MINE/Rituxan	Autologous HCT	63	Marrow	ND	ND	^1-153	^1-153
FH16020	46/M	NHL/rel MCL	6x CHOP, Rituxan, Cy/VP16/BCNU	Autologous HCT	45	Blood	8.22	3.83	^1-153	^1-153
UL744	62/M	NHL/rel high grade T cell	4x CHOP, 2x Dexa-BEAM, HD-BEAM, Cy/Pred, HAM, Dexa-BEAM	Age + autologous HCT	29	Marrow	3.3	0.6	B^†C^*	B^†C^*
FH15780	62/F	NHL/PR MCL	4x CNOP, 2x Mito/Flu, Flu, Rituxan, ESHAP, Cy/VP16, 3x Topo/Taxol	Age	41	Marrow	1.17	ND	^1-153	^1-153
FH17028	52/M	WM/refr	Chlorambucil, 14x Flu, Cladribine, Rituxan	Age	184	Marrow	2.19	ND	^1-153	^1-153
FH15390	6/M	MDS/RA	No prev tx	Shwachman-Diamond syndrome	9	Marrow	ND	ND	^1-153	^1-153
SPN2219	41/M	MDS/CMML	Pred, Hu	Congestive heart failure and performance status	6	Blood	12.30	2.00	^1-153	^1-153
SPN2269	39/M	MDS/RAEB-T	No prev tx	Poor performance status, recurrent infections, type II diabetes	6	Blood	7.4	0.8	^1-153	^1-153
UL760	33/F	MDS/CMML	2x Ida/Ara-C	Aspergillosis	6	Blood	7.9	5.1	B^†C^*	B^†C^*
FH11799	55/F	MDS/RAEB	No prev tx	Age	165	Marrow	4.07	0.3	^1-153	^1-153
FH15608	40/F	MDS/AML/CR	3x Ida/Ara-C	Reflex sympathetic dystrophy, chr. foot ulcer, chr. pain syndrome	15	Blood	1.48	1.47	^1-153	^1-153
FH16391	46/M	MDS/AML refr	6x CVAP/Bleomycin, Cy/VP16, BEAC, Ara-C/Topo	Autologous HCT	9	Marrow	2.49	0.17	^1-153	^1-153
FH15595	65/F	MDS/MPS	Hu	Age	11	Blood	2.21	3.08	^1-153	^1-153
UL664	40/M	MM/rel	10x Vcr/Cy/Mel, Cy, 3x VAD, TBI/Mel, HD-Mel, 2x Benda/Pred	2x Autologous HCT	109	Marrow	2.7	0.6	C^* DQB1^*	C^* DQB1^*
UL714	59/M	MM/rel	9x Mel, 2x VAD, 2x HD-Cy, HD-Dexa, 1x Mel	Age	56	Blood	4.1	4.3	^1-153	C^*
UL733	48/F	MM/rel	Dexa, 2x VP16/Ifo, TBI/Mel, 2x Benda	Autologous HCT	73	Blood	21.1	8.5	^1-153	^1-153
UL747	49/M	MM/PR	13x Mel/Pred, 3x VAD, 1x HD-Cy, 2x HD-Mel, 3x Thalid/Cy/VP16/Dexa, Thalid	2x Autologous HCT	65	Marrow	5.2	0.4	^1-153	^1-153
UL753	50/M	MM/PR	6x VAD	Age	21	Blood	15.6	3.9	C^*	C^*
FH15711	41/M	MM/refr	VAD, DCEP/Thalid, CAD, Dexa/Thalid, Dexa	Patient's request	31	Blood	5.50	2.27	^1-153	^1-153
UL765	61/M	MM/PR	1x Mel/Pred, 3x Ifo/Epi, 1x HD-Mel, IFN, 1x Ifo/Epi, 6x Benda/Vbl, IFN	Age + autologous HCT	66	Blood	6.3	4.3	A^†C^*	A^†C^*
FH14886	61/M	MM/refr	3x VAD, HD-Mel	Age + autologous HCT	30	Blood	7.43	1	^1-153	^1-153
UL703	30/M	PNH	CSP, Pred	Sarcoidosis	15	Blood	5.6	3.2	C^*	^1-153

UPN	Age (y)/sex	Disease + status	Therapy before HCT	Contraindications to conventional HCT	Mos. from Dx to HCT	Source of HSC	CD34⁺ cells × 10⁶/kg	CD3⁺ cells × 10⁸/kg	HLA mismatch
UPN	Age (y)/sex	Disease + status	Therapy before HCT	Contraindications to conventional HCT	Mos. from Dx to HCT	Source of HSC	CD34⁺ cells × 10⁶/kg	CD3⁺ cells × 10⁸/kg	Rejection vector	GVHD vector
SPN2292	21/M	ALL/CR2	3x Dnr/Vcr/Asp/Pred, MTX, Flu/Ara-C/Ida	Hepatic dysfunction, aspergillosis sinuses	64	Blood	7.1	1.2	^1-153	^1-153
UL755	27/M	ALL/CR2	1x Cy/Dnr/Asp/Vcr, 2x HAM, purinetol/MTX	S.p. ventilation for int. pneumonia + septicemia	59	Blood	6.1	5.3	C^†	C^†
SPN2252	57/F	AML/CR1	2x Ida/Ara-C	Age	5	Marrow	3.5	0.4	^1-153	^1-153
UL676	45/M	AML/CR2	1x Ida/Ara-C, 1x Mito-FLAG	Autologous HCT	15	Blood	5.8	3.1	DQBI^†	DQBI^†
UL652	59/M	AML/CR3	4x Ida/Ara-C, 2x Mito-FLAG, 1x TBI/Ara-C, VP16	Age + autologous HCT	27	Blood	9.6	2.1	A^*	A^*
FH15303	59/F	AML/CR3	3x Ida/Ara-C, 2x Mito/VP16, Topo/Ara-C, i.t. MTX, craniospinal RT	Age	21	Blood	2.6	3.8	^1-153	^1-153
UL637	53/M	AML/CR3	3x Ida/Ara-C, Ara-C/Mito/Ida/VP16, 1x Mito/FLAG	Age + aspergillosis + liver cirrhosis	36	Blood	4.7	5.2	C^*	^‡
FH16411	40/F	AML/CR4	4x Ida/Ara-C, 2x Ara-C, HD-Cy, i.t. MTX, craniospinal RT	Suspected aspergillosis + hepatic dysfunction	21	Blood	16.8	5.5	^1-153	^1-153
UL665	51/F	AML/PR2	3x Ida/Ara-C, 2x Mito-FLAG	Age + s.p. ventilation for int. pneumonia + septicemia	35	Blood	5.00	3.7	^1-153	^1-153
UL668	61/M	AML/progression	4x Ida/Ara-C, 2x Mito/VP16, 3x Mito/FLAG, HD-BuCy/VP16, CHOP, vindesine	Age + autologous HCT	82	Blood	2.87	2.09	^1-153	^1-153
UL680	60/F	AML/progression	1x ICE, 1x HAM, 1x Mito-FLAG, 1x HAM	Age	21	Blood	3.3	1.39	A^B^†C^	A^B^†C^
UL692	48/F	AML/rel1	1x Ida/Ara-C, 3x Mito/Ara-C	Age + Karnofsky 60	12	Blood	14.3	3.7	B^†	B^†
UL656	47/M	CLL/PR	HD-chlorambucil, 6x Flu/Cy	Age + patient decision	9	Blood	21.6	4.5	^1-153	^1-153
UL698	50/M	CLL/PR	6x CHOP, 2x Flu/Cy, 1x Dexa-BEAM	Age + s.p. recurrent septicemias	77	Blood	5.5	3.4	^1-153	^1-153
FH16078	59/M	CLL/rel	Chlorambucil, 14x Flu, 6x Flu/Cy	Age	78	Blood	12.80	2.27	^1-153	^1-153
UL597	48/M	CML/AP	Hu/IFN, 1x Ida/Ara-C, HD-Bu, Hu/IFN	Autologous HCT	41	Blood	10.3	4.6	C^*	C^*
UL641	45/F	CML/AP	1x Ida/Ara-C, IFN/Hu, IFN/Ara-C	Adipositas, hypertension	30	Blood	3.2	2.6	^‡	^‡
UL670	47/M	CML/AP	Hu, Ida/Ara-C, Hu/IFN, HD-Bu, Hu/IFN	Autologous HCT	42	Marrow	1.7	0.22	C	C
UL672	50/F	CML/CP	1x Ida/Ara-C, IFN/Hu	Age	32	Blood	6	3.9	^1-153	^1-153
UL695	46/M	CML/AP	Hu, IFN, Ida/Ara-C, HD-Bu	Autologous HCT	63	Blood	14.2	3.8	A^†	A^†
UL709	62/M	CML/CP	Hu/IFN, Ara-C	Age	24	Blood	5.3	6.2	^1-153	^1-153
UL725	57/M	CML/CP	Hu, IFN, Hu	Age	80	Blood	4.5	1	^1-153	^1-153
UL730	57/M	CML/CP	Hu/IFN	Age	75	Blood	5.8	3.3	C^*	A^† C^*
									DQB1^*	DQB1^*
UL735	57/F	CML/CP	Hu, Ida/Ara-C, IFN/Hu, HD-Bu, Ara-C/IFN, Hu, Tg	Age + autologous HCT	26	Blood	5.5	10	^1-153	^1-153
UL754	54/M	CML/CP2	Hu, IFN, Ida/Ara-C, HD-Bu, IFN, Hu, Vcr/Pred, ST1571, Ida/Ara-C	Age + autologous HCT	74	Blood	6.1	3.4	C^* DRB1^† DQB1^*	C^* DRB1^†
UC001	36/F	CML/AP	Hu/IFN, BU/mel, Ida/Ara-C/DLI, Flu/ATG/TLI, FLAG	Previous HLA-id sibling HCT	24	Marrow	2.76	0.45	^‡	^‡
UC002	33/M	CML/BC	IFN/Hu, Cy/TBI, Mito/Flu/Ara-C, Mylotarg	Previous HLA-matched unrelated HCT	52	Marrow	1.88	0.29	^‡	^‡
FH15764	43/M	Hodgkin disease/rel	3x ABVD, 3x Chl-VPP, Dnr, Vbl, 6x VP16, RT pelvic nodes, L hemipelvis/groin, BEAC	Autologous HCT	32	Blood	5.65	1.54	^1-153	^1-153
UL701	40/M	NHL/refr B-cell	8x CHOP, Vbl/Dexa, Dexa-BEAM, HD-MTX, HD-BEAM, Bu/Thiotepa	2x Autologous HCT	21	Blood	6.2	4.9	A^*	A^*
SPN1463	45/M	NHL/rel diff. large cell	MOPP/ABV, radiotherapy, 2x DHAP, HD-Cy, Vcr, VP16, Mito/Mel, Rituxan, Cy/Flu, Taxol	Autologous HCT	41	Blood	3.60	1.7	C^*	^1-153
FH13715	42/M	NHL/rel MCL	6x CHOP, Cy/VP16, 2x Gemcitabine, 2x MINE/Rituxan	Autologous HCT	63	Marrow	ND	ND	^1-153	^1-153
FH16020	46/M	NHL/rel MCL	6x CHOP, Rituxan, Cy/VP16/BCNU	Autologous HCT	45	Blood	8.22	3.83	^1-153	^1-153
UL744	62/M	NHL/rel high grade T cell	4x CHOP, 2x Dexa-BEAM, HD-BEAM, Cy/Pred, HAM, Dexa-BEAM	Age + autologous HCT	29	Marrow	3.3	0.6	B^†C^*	B^†C^*
FH15780	62/F	NHL/PR MCL	4x CNOP, 2x Mito/Flu, Flu, Rituxan, ESHAP, Cy/VP16, 3x Topo/Taxol	Age	41	Marrow	1.17	ND	^1-153	^1-153
FH17028	52/M	WM/refr	Chlorambucil, 14x Flu, Cladribine, Rituxan	Age	184	Marrow	2.19	ND	^1-153	^1-153
FH15390	6/M	MDS/RA	No prev tx	Shwachman-Diamond syndrome	9	Marrow	ND	ND	^1-153	^1-153
SPN2219	41/M	MDS/CMML	Pred, Hu	Congestive heart failure and performance status	6	Blood	12.30	2.00	^1-153	^1-153
SPN2269	39/M	MDS/RAEB-T	No prev tx	Poor performance status, recurrent infections, type II diabetes	6	Blood	7.4	0.8	^1-153	^1-153
UL760	33/F	MDS/CMML	2x Ida/Ara-C	Aspergillosis	6	Blood	7.9	5.1	B^†C^*	B^†C^*
FH11799	55/F	MDS/RAEB	No prev tx	Age	165	Marrow	4.07	0.3	^1-153	^1-153
FH15608	40/F	MDS/AML/CR	3x Ida/Ara-C	Reflex sympathetic dystrophy, chr. foot ulcer, chr. pain syndrome	15	Blood	1.48	1.47	^1-153	^1-153
FH16391	46/M	MDS/AML refr	6x CVAP/Bleomycin, Cy/VP16, BEAC, Ara-C/Topo	Autologous HCT	9	Marrow	2.49	0.17	^1-153	^1-153
FH15595	65/F	MDS/MPS	Hu	Age	11	Blood	2.21	3.08	^1-153	^1-153
UL664	40/M	MM/rel	10x Vcr/Cy/Mel, Cy, 3x VAD, TBI/Mel, HD-Mel, 2x Benda/Pred	2x Autologous HCT	109	Marrow	2.7	0.6	C^* DQB1^*	C^* DQB1^*
UL714	59/M	MM/rel	9x Mel, 2x VAD, 2x HD-Cy, HD-Dexa, 1x Mel	Age	56	Blood	4.1	4.3	^1-153	C^*
UL733	48/F	MM/rel	Dexa, 2x VP16/Ifo, TBI/Mel, 2x Benda	Autologous HCT	73	Blood	21.1	8.5	^1-153	^1-153
UL747	49/M	MM/PR	13x Mel/Pred, 3x VAD, 1x HD-Cy, 2x HD-Mel, 3x Thalid/Cy/VP16/Dexa, Thalid	2x Autologous HCT	65	Marrow	5.2	0.4	^1-153	^1-153
UL753	50/M	MM/PR	6x VAD	Age	21	Blood	15.6	3.9	C^*	C^*
FH15711	41/M	MM/refr	VAD, DCEP/Thalid, CAD, Dexa/Thalid, Dexa	Patient's request	31	Blood	5.50	2.27	^1-153	^1-153
UL765	61/M	MM/PR	1x Mel/Pred, 3x Ifo/Epi, 1x HD-Mel, IFN, 1x Ifo/Epi, 6x Benda/Vbl, IFN	Age + autologous HCT	66	Blood	6.3	4.3	A^†C^*	A^†C^*
FH14886	61/M	MM/refr	3x VAD, HD-Mel	Age + autologous HCT	30	Blood	7.43	1	^1-153	^1-153
UL703	30/M	PNH	CSP, Pred	Sarcoidosis	15	Blood	5.6	3.2	C^*	^1-153

Antigen-level mismatch.

†

Allele-level mismatch.

‡

Antigen match.

F1-153

Allele match.

Forty-three patients were mismatched in addition at DPB1 for either one or both alleles by rejection vector (n = 43) or by GVHD vector (n = 37).

ND indicates not done.

View Large

This Feature Is Available To Subscribers Only